Braveheart Bio Reports Q2 2026 Financial Results

San Francisco, California, USA - Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, reported its unaudited financial results for the second quarter ended June 30, 2026, alongside a business update.

The company highlighted the initiation of the Phase 3 LIONHEART-HCM trial evaluating BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). Additionally, cash and cash equivalents stood at $122.8 million as of June 30, 2026, which increases to $527.3 million on an as-adjusted basis after giving effect to the company's initial public offering completed in August 2026.

• Financial Results: Research and development expenses were $11.1 million for the second quarter of 2026, while general and administrative expenses reached $4.8 million. Net loss for the quarter was $15.0 million, and net loss attributable to common stockholders was $18.6 million, or $2.51 per basic and diluted share.
• Clinical Updates: Braveheart Bio initiated the global Phase 3 LIONHEART-HCM trial for oHCM and expects to initiate the NOBLEHEART-HCM Phase 3 trial in non-obstructive HCM in the first half of 2027.
• Capital Milestones: The company raised gross proceeds of $60.0 million from its Series A preferred stock financing in April 2026 and approximately $439.9 million in gross proceeds from its initial public offering in August 2026.